What is the significance of molecular remission in multiple myeloma

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 2, 2007, Pages 91-95

  Tricot, Guido J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Autotransplantation; Chain Reaction; Minimal residual disease; Multiple myeloma; Polymerase

Indexed keywords

M PROTEIN;

ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; FOLLOW UP; HUMAN; INTENSIVE CARE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; MYELOMA CELL; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; SAFETY;

DISEASE PROGRESSION; HUMANS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33947370433     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20-32.
2. Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003;9:4-37.
3. Barlogie B, Tricot G, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006;135: 158-164.
4. Fassas A, Barlogie B, Rasmussen E, et al. Low incidence of complete remission but comparable event-free survival (EFS) and overall survival (OS) with a history of prior monoclonal gammopathy of underdetermined significance (MGUS) or smoldering myeloma (SMM) among patients receiving total therapy 2 (TT2). Blood. 2004;104:Abstract 932.
5. Durie B, Salmon S. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36: 842-854.
6. Barlogie B, Alexanian R, Pershouse M, et al. Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest. 1985; 76:765-769.
7. Bradwell, A. Serum Free Light Chain Assays. 4th ed. Birmingham, UK: The Binding Site; 2003.
8. Klein B, Zhang X, Lu, Z, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-872.
9. Van Der Velden V, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013-1034.
10. van Dongen J, Seriu T, Panzer-Grumayer E, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet. 1998;352:1731-1738.
11. Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22:1460-1468.
12. Merx K, Muller M, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia. 2002;16:1579-1583.
13. Ladetto M, Donovan J, Harig S, et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant. 2000;6:241-253.
14. Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol. 1999;17:208-215.
15. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or aurologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol. 2000;18:2273-2281.
16. Perez-Simon JA, Caballero D, Mateos MV, et al. Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation. Leuk Lymphoma. 2004;45:1725-1729.
17. Kroger N. Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma. Leuk Lymphoma. 2005;46:813-821.
18. Gahrton G. Progress in hematopoietic stem cell transplantation in multiple myeloma. Curr Opin Hematol. 2005;12:463-470.
19. Bakkus M, Bouko Y, Samson D, et al. Post-transplantation tumor load in bone marrow assessed by quantitative ASO-PCR is a prognostic parameter in multiple myeloma. Br J Haematol. 2004;126:1365-2141.
20. Gazitt Y, Reading C, Hoffman R, et al. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood. 1995;86:381-389.
21. Gazitt Y, Tian E, Barlogie B, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood. 1996;87:805-811.
22. Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102:1927-1929.